These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 18927241

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
    Mao ZL, Townsend RW, Gao Y, Wheeler JJ, Kastrissios H, Keirns J.
    J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers.
    Mao ZL, Alak A, Wheeler JJ, Keirns J.
    Drug Metab Lett; 2011 Apr; 5(2):114-25. PubMed ID: 21457140
    [Abstract] [Full Text] [Related]

  • 8. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN, Eschenhagen T.
    Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN.
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E, Atrial Arrhythmia Conversion Trial Investigators.
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN, Mangal B.
    BMC Cardiovasc Disord; 2016 May 28; 16():113. PubMed ID: 27233239
    [Abstract] [Full Text] [Related]

  • 18. Atrial selective effects of intravenously administered vernakalant in conscious beagle dogs.
    Bechard J, Pourrier M.
    J Cardiovasc Pharmacol; 2011 Jul 28; 58(1):49-55. PubMed ID: 21753258
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA.
    Clin Pharmacol Ther; 2004 Dec 28; 76(6):536-44. PubMed ID: 15592325
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI.
    J Clin Psychopharmacol; 2009 Feb 28; 29(1):39-43. PubMed ID: 19142106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.